METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough prostate cancer: drug combo trial launches
Disease control OngoingThis Phase 3 trial tests whether adding the experimental drug mevrometostat to standard enzalutamide can slow cancer growth better than current treatments in men with metastatic castration-resistant prostate cancer that has progressed after abiraterone. About 600 participants wil…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial is testing a new treatment called TmPSMA-02 for men with metastatic castrate-resistant prostate cancer that has progressed after standard therapies. The treatment uses the patient's own immune cells (T cells) that are genetically modified to recognize and a…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for advanced prostate cancer: radioactive drug vs standard therapy
Disease control OngoingThis study tests whether a radioactive drug called radium-223 works better than standard hormone-blocking pills (ARPI) for men with prostate cancer that has spread to the bones and is no longer responding to initial hormone therapy. About 654 participants will receive either radi…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE4 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New alpha radiation therapy shows promise for tough prostate cancer
Disease control OngoingThis early-stage study tests a new radioactive drug called AB001 in 80 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug delivers a powerful alpha radiation dose directly to cancer cells. The main goals are to check safety and find the bes…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: ARTBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC